Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Edesa Biotech Inc

Healthcare US EDSA

5.46USD
-1.63(22.99%)

Last update at 2026-06-05T20:02:00Z

Day Range

5.017.61
LowHigh

52 Week Range

0.729.37
LowHigh

Fundamentals

  • Previous Close 7.09
  • Market Cap52.69M
  • Volume763214
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.25264M
  • Revenue TTM0.00050M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.31M
  • Diluted EPS TTM-1.07

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -7.18472M -6.16925M -8.37361M -17.54812M -13.34235M
Minority interest - - - - -
Net income -7.18552M -6.17005M -8.37442M -17.54892M -13.34315M
Selling general administrative 4.24M 4.13M 4.43M 5.04M 5.73M
Selling and marketing expenses - - 0.18M - -
Gross profit -0.11927M -0.18605M -0.18347M -0.11819M -0.11879M
Reconciled depreciation 0.12M 0.19M 0.18M 0.12M 0.12M
Ebit -7.18472M -6.16925M -9.22276M -18.37079M -23.68133M
Ebitda -7.06545M -5.98320M -9.22276M -17.59053M -13.34049M
Depreciation and amortization 0.12M 0.19M 0.18M 0.78M 10.34M
Non operating income net other - - - - -
Operating income -7.91157M -7.01474M -9.22276M -18.37079M -23.68133M
Other operating expenses 7.91M 7.01M 9.22M 17.59M 13.34M
Interest expense - - - 0.82M 0.12M
Tax provision 0.00080M 0.00080M 0.00080M 0.00080M 0.00080M
Interest income 0.00256M 0.15M 0.29M 0.06M 0.01M
Net interest income 0.00256M 0.15M 0.29M 0.06M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00080M 0.00080M 0.00080M 0.00080M 0.00080M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00050M
Total operating expenses 7.79M 7.01M 9.22M 17.59M 13.34M
Cost of revenue 0.12M 0.19M 0.18M 0.12M 0.12M
Total other income expense net 0.73M 0.85M 0.85M 0.82M 10.34M
Discontinued operations - - - - -
Net income from continuing ops -7.18552M -6.17005M -8.37442M -17.54892M -13.34315M
Net income applicable to common shares - - - -17.54892M -13.34315M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 13.53M 3.81M 8.89M 11.58M 14.58M
Intangible assets 1.98M 2.08M 2.18M 2.28M 2.38M
Earning assets - - - - -
Other current assets 0.08M 0.37M 0.45M 2.00M 0.95M
Total liab 1.08M 1.83M 1.84M 2.18M 1.53M
Total stockholder equity 12.45M 1.98M 7.05M 9.39M 13.06M
Deferred long term liab - - - - -
Other current liab 1.08M 1.81M 1.75M 2.12M 1.38M
Common stock 54.52M 47.24M 46.64M 42.47M 34.89M
Capital stock 63.78M 47.24M 46.64M 42.47M 34.89M
Retained earnings -65.91097M -58.58901M -52.41897M -44.04455M -26.49563M
Other liab - - - 0.04M 0.05M
Good will - - - - -
Other assets - - - 2.00M 14.58M
Cash 10.79M 1.04M 5.36M 7.09M 7.84M
Cash and equivalents - - - - -
Total current liabilities 1.08M 1.83M 1.82M 2.14M 1.46M
Current deferred revenue - - - - -
Net debt -10.79217M -1.01745M -5.26691M -7.07194M -7.73994M
Short term debt - 0.02M 0.07M 0.02M 0.08M
Short long term debt - - - - -
Short long term debt total - 0.02M 0.09M 0.02M 0.10M
Other stockholder equity 14.75M 13.58M 13.04M 11.18M 4.67M
Property plant equipment - - - 0.03M 0.11M
Total current assets 11.51M 1.68M 6.44M 9.09M 12.09M
Long term investments - - - - -
Net tangible assets - - - 7.11M 10.68M
Short term investments - - - - -
Net receivables 0.64M 0.27M 0.63M 1.26M 3.30M
Long term debt - - - - -
Inventory - - - -1.25545M -
Accounts payable 1.08M 1.81M - 2.12M 1.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.16577M -0.24261M -0.21465M -0.21360M -0.20526M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.04M 0.04M 0.17M 0.17M -
Deferred long term asset charges - - - - -
Non current assets total 2.02M 2.14M 2.45M 2.48M 2.49M
Capital lease obligations 0.00000M 0.02M 0.09M 0.02M 0.10M
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - - 0.00004M -0.00566M -0.00615M
Change to liabilities - - - 0.88M -0.12472M
Total cashflows from investing activities - - - -0.00566M -0.00615M
Net borrowings 0.00000M -0.02953M - - -
Total cash from financing activities 17.03M 0.59M 4.83M 11.63M 14.17M
Change to operating activities - - - -0.01950M -0.28136M
Net income -7.18552M -6.17005M -8.37442M -17.54892M -13.34315M
Change in cash 9.75M -4.32408M -1.72952M -0.74834M 0.63M
Begin period cash flow 1.04M 5.36M 7.09M 7.84M 7.21M
End period cash flow 10.79M 1.04M 5.36M 7.09M 7.84M
Total cash from operating activities -7.32226M -4.89020M -6.63648M -12.27930M -13.66493M
Issuance of capital stock 17.60M 0.73M 4.35M 11.96M 12.66M
Depreciation 0.12M 0.19M 0.18M 0.12M 0.12M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.37799M 0.36M 0.56M 2027.45M -3.22995M
Sale purchase of stock - - - - -
Other cashflows from financing activities 9.88M -0.10782M 0.49M -0.32806M 1.51M
Change to netincome - - - 2.26M 3.20M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00566M 0.00615M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.98565M 0.57M 0.31M 2.89M -3.63604M
Stock based compensation 0.73M 0.54M 1.25M 2.26M 3.20M
Other non cash items - -0.01477M 0.31M 2.38M 3.31M
Free cash flow -7.32226M -4.89020M -6.63648M -12.28496M -13.67108M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EDSA
Edesa Biotech Inc		 -1.63 22.99% 5.46 - 0.18 130462.29 12.95 140491.25 -1.2523
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Edesa Biotech Inc

100 Spy Court, Markham, ON, Canada, L3R 5H6

Key Executives

Name Title Year Born
Dr. Pardeep Nijhawan FRCPC, M.D. CEO, Company Sec. & Director 1971
Dr. Michael J. Brooks M.B.A., Ph.D. Pres 1978
Ms. Kathi Niffenegger CPA, CPA Chief Financial Officer 1957
Mr. Gary Koppenjan VP of Investor Relations & Communications NA
Mr. Rajan Puri Sr. VP of Manufacturing NA
Dr. Pardeep Nijhawan FRCPC, M.D. CEO, Company Secretary & Director 1971
Dr. Michael J. Brooks M.B.A., Ph.D. President 1978
Mr. Stephen L. Lemieux BA, C.P.A., CA, CPA, MMPA Chief Financial Officer 1977
Dr. Michael J. Brooks M.B.A., Ph.D. President 1979
Mr. Peter John Weiler M.B.A, M.Sc. Chief Financial Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions